NuVasive, Inc. (NASDAQ:NUVA)‘s stock had its “buy” rating reaffirmed by Gabelli in a report released on Thursday.

NUVA has been the subject of several other research reports. Needham & Company LLC restated a “hold” rating on shares of NuVasive in a report on Friday, July 28th. Royal Bank Of Canada lifted their price target on NuVasive from $76.00 to $85.00 and gave the stock an “outperform” rating in a report on Tuesday, June 6th. Cowen and Company reiterated an “outperform” rating and set a $83.00 price target on shares of NuVasive in a report on Monday, September 18th. Barclays PLC reiterated a “buy” rating and set a $80.00 price target on shares of NuVasive in a report on Wednesday, August 2nd. Finally, Piper Jaffray Companies reiterated an “overweight” rating and set a $90.00 price target on shares of NuVasive in a report on Wednesday, August 9th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and twelve have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $79.92.

NuVasive (NASDAQ NUVA) opened at 54.25 on Thursday. The firm has a 50-day moving average price of $62.55 and a 200-day moving average price of $71.98. The stock has a market cap of $2.76 billion, a P/E ratio of 85.43 and a beta of 1.08. NuVasive has a 52 week low of $52.85 and a 52 week high of $81.68.

NuVasive (NASDAQ:NUVA) last announced its quarterly earnings data on Thursday, July 27th. The medical device company reported $0.46 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.44 by $0.02. The company had revenue of $260.60 million during the quarter, compared to analysts’ expectations of $261.95 million. NuVasive had a return on equity of 13.04% and a net margin of 3.50%. NuVasive’s revenue for the quarter was up 10.3% compared to the same quarter last year. During the same quarter last year, the company earned $0.40 EPS. On average, equities research analysts predict that NuVasive will post $2.00 EPS for the current year.

WARNING: “Gabelli Reiterates Buy Rating for NuVasive, Inc. (NUVA)” was posted by Daily Political and is owned by of Daily Political. If you are accessing this article on another domain, it was illegally copied and republished in violation of international trademark & copyright law. The legal version of this article can be accessed at https://www.dailypolitical.com/2017/09/22/gabelli-reiterates-buy-rating-for-nuvasive-inc-nuva.html.

In other news, CEO Gregory T. Lucier acquired 2,000 shares of the stock in a transaction on Tuesday, August 29th. The stock was acquired at an average cost of $61.52 per share, for a total transaction of $123,040.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Gregory T. Lucier acquired 5,000 shares of the stock in a transaction on Thursday, August 17th. The shares were purchased at an average price of $66.22 per share, with a total value of $331,100.00. The disclosure for this purchase can be found here. Over the last 90 days, insiders have acquired 14,850 shares of company stock valued at $955,598. Company insiders own 1.20% of the company’s stock.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Navellier & Associates Inc raised its position in NuVasive by 5.2% during the second quarter. Navellier & Associates Inc now owns 74,387 shares of the medical device company’s stock valued at $5,722,000 after purchasing an additional 3,696 shares in the last quarter. Broadfin Capital LLC acquired a new position in NuVasive during the second quarter valued at approximately $4,300,000. Dynamic Technology Lab Private Ltd acquired a new position in NuVasive during the second quarter valued at approximately $501,000. Public Employees Retirement System of Ohio raised its position in NuVasive by 68.3% during the second quarter. Public Employees Retirement System of Ohio now owns 115,372 shares of the medical device company’s stock valued at $8,874,000 after purchasing an additional 46,805 shares in the last quarter. Finally, Disciplined Growth Investors Inc. MN raised its position in NuVasive by 4.3% during the second quarter. Disciplined Growth Investors Inc. MN now owns 70,657 shares of the medical device company’s stock valued at $5,435,000 after purchasing an additional 2,922 shares in the last quarter.

NuVasive Company Profile

Nuvasive, Inc is a medical device company. The Company focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine surgery. Its product portfolio focuses on applications for spine fusion surgery, including biologics used to aid in the spinal fusion process.

Analyst Recommendations for NuVasive (NASDAQ:NUVA)

Receive News & Ratings for NuVasive Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuVasive Inc. and related companies with MarketBeat.com's FREE daily email newsletter.